Chronic myeloproliferative neoplasms

From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29:3907–13.

    Article  Google Scholar 

  2. 2.

    Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664–70.

    CAS  Article  Google Scholar 

  3. 3.

    Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl J Med. 2004;350:114–24.

    CAS  Article  Google Scholar 

  4. 4.

    Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057–69.

    Article  Google Scholar 

  5. 5.

    Ferrari A, Carobbio A, Masciulli A, Ghirardi A, Finazzi G, De Stefano V, et al. Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis. Haematologica. 2019;104:2391–9.

    CAS  Article  Google Scholar 

  6. 6.

    Griesshammer M, Kiladjian JJ, Besses C. Thromboembolic events in polycythemia vera. Ann Hematol. 2019;98:1071–82.

    Article  Google Scholar 

  7. 7.

    Hultcrantz M, Björkholm M, Dickman PW, Landgren O, Derolf Å, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168:317–25.

    Article  Google Scholar 

  8. 8.

    Spivak JL. Myeloproliferative neoplasms. N. Engl J Med. 2017;377:895–6.

    PubMed  Google Scholar 

  9. 9.

    Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17–23.

    CAS  PubMed  Google Scholar 

  10. 10.

    Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098–103.

    Article  Google Scholar 

  11. 11.

    Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, et al. Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease. J Clin Oncol. 2016;34:151–9.

    CAS  Article  Google Scholar 

  12. 12.

    Najean Y, Dresch C, Rain JD. The very-long-term course of polycythaemia: a complement to the previously published data of the Polycythaemia Vera Study Group. Br J Haematol. 1994;86:233–5.

    CAS  Article  Google Scholar 

  13. 13.

    Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N. Engl J Med. 2013;368:22–33.

    CAS  Article  Google Scholar 

  14. 14.

    Spivak JL. How I treat polycythemia vera. Blood. 2019;134:341–52.

    CAS  Article  Google Scholar 

  15. 15.

    Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065–72.

    CAS  Article  Google Scholar 

  16. 16.

    Quintás-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418–24.

    Article  Google Scholar 

  17. 17.

    Kiladjian JJ, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016;30:776–81.

    CAS  Article  Google Scholar 

  18. 18.

    Kiladjian JJ. Long-term treatment with interferon alfa for myeloproliferative neoplasms. Lancet Haematol. 2017;4:e150–e1.

    Article  Google Scholar 

  19. 19.

    Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR, et al. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019;134:1498–509.

    CAS  Article  Google Scholar 

  20. 20.

    Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, et al. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia. 2019;33:2974–8.

    CAS  Article  Google Scholar 

  21. 21.

    Silver RT. Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet. 1988;2:403.

    CAS  Article  Google Scholar 

  22. 22.

    Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196–e208.

    Article  Google Scholar 

  23. 23.

    Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762–9.

  24. 24.

    Kiladjian J-J, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Thromboembolic risk reduction and high rate of complete molecular response with long-term use of ropeginterferon alpha-2b in polycythemia vera: results from a randomized controlled study. Blood. 2019;134 Suppl 1:553.

    Article  Google Scholar 

  25. 25.

    Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, et al. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017;15(10):1193–207.

    Article  Google Scholar 

  26. 26.

    Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3(11):1729–37.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Tiziano Barbui.

Ethics declarations

Conflict of interest

JJK served in advisory boards for Novartis, AOP Orphan, BMS. TB served in advisory boards for Novartis, AOP Orphan, Italfarmaco.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kiladjian, J., Barbui, T. From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera?. Leukemia (2020). https://doi.org/10.1038/s41375-020-0984-9

Download citation